stockrowRecursion Pharmaceuticals, Inc.
RXRX Healthcare Biotechnology
Recursion Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $74.7 million, up 26.9% from fiscal 2024.
- Revenue
- +258.5%
- EPS
- +39.1%
- Free cash flow
- +33.8%
- Total debt
- −99.2%
Quarter to September 2026, against a year earlier
Follow RXRX
Alert me
Recursion Pharmaceuticals, Inc. (RXRX) EV/FCF
As of 5 November 2026, Recursion Pharmaceuticals, Inc. (RXRX) trades at a EV/FCF of −4.3×. Over the past ten years it has ranged from −48.2× (July 2021) to −1.4× (March 2026); the current reading is higher than 59% of that period.
EV/FCF, daily
Embed this chart
Annual newest first
| Period | EV/FCF | Change |
|---|---|---|
| FY2025 | −2.9× | — |
| FY2024 | −3.4× | — |
| FY2023 | −5.5× | — |
| FY2022 | −6.4× | — |
| FY2022 | −12.7× | — |
| FY2021 | −11.9× | — |
| FY2021 | −6.2× | — |
| FY2020 | −6.2× | — |
| FY2020 | −6.2× | — |
| FY2019 | −6.2× | — |
Quarterly newest first
| Period | EV/FCF | Change |
|---|---|---|
| Sep 2026 | −5.4× | — |
| Jun 2026 | −4.0× | — |
| Mar 2026 | −3.0× | — |
| Dec 2025 | −2.9× | — |
| 23 more quarters | Free account |
Against its own ten years
EV/FCF against peers
| Company | EV/FCF |
|---|---|
| PVLA Palvella Therapeutics, Inc. compare | −62.4× |
| MBX MBX Biosciences, Inc. compare | −22.3× |
| NAMS NewAmsterdam Pharma Company N.V. compare | −11.4× |
| PHVS Pharvaris N.V. compare | −10.5× |
| CLDX Celldex Therapeutics, Inc. compare | −6.2× |
| BHVN Biohaven Ltd. compare | −4.5× |
| RXRX Recursion Pharmaceuticals, Inc. | −4.3× |
| ADMA ADMA Biologics Inc compare | 25.2× |
| VCEL Vericel Corporation compare | 42.8× |
What EV/FCF is
EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))
More on RXRX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement